ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies

Ads

You May Also Like

Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements

BERKELEY HEIGHTS, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ...